Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function

• Status: Withdrawn
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating vestibular function prior to surgery, even if vestibular function is absent according to modern assessment techniques

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University
• Treatments: Gentamicins

Criteria

Inclusion Criteria:

• Vestibular schwannoma advised to surgical treatment

• No measurable remaining vestibular function

Exclusion Criteria:

• impaired decision making

• neurofibromatosis

• signs for central dysfunction

• remaining vestibular function

• Patients are advised not to participate in the gentamicin arm if

• hearing is better than 30 deciBel (dB) in pure tone average (500, 1000, 2000, 3-4000 Hz) and speech discrimination better than 70%

• the neurosurgeon aim at hearing preservation surgery and do not want to risk gentamicin associated hearing loss